Agilent to appeal patent office decision on CRISPR gRNA patents
Agilent respectfully disagrees with the PTAB’s opinion of unpatentability in view of prior art previously considered by the USPTO during its primary examination
Agilent respectfully disagrees with the PTAB’s opinion of unpatentability in view of prior art previously considered by the USPTO during its primary examination
These announcements are in line with Croda Pharma’s strategy to “Empower Biologics Delivery” and follows news on investments, earlier this year, to expand Croda Pharma’s global manufacturing capabilities to enable the next generation vaccines and therapeutic drugs.
The facility will have a capacity to manufacture upto 3 million tubes monthly
Dr. Reddy's Laboratories has been issued a Form 483 with four observations
Nous-209 has been developed using the Nouscom's viral vector platform
Cooperative agreement with U.S. Government to advance U.S. biopharma industry and ensure pandemic preparedness
The New State-of-Art OligoPilot 2000 solid-phase synthesizer adds cGMP manufacturing capacity to support and accelerate clinical and commercial oligonucleotide programs.
The USFDA had classified the inspection as "Official Action Indicated" (OAI).
Subscribe To Our Newsletter & Stay Updated